- Lamivudine shows potential as a treatment for diabetic macular edema (DME).
- It significantly improved visual acuity in a small randomized study.
- The oral drug may offer a more convenient and cost-effective treatment option.
- Lamivudine's mechanism of action differs from existing treatments for DME.
- It may be effective as monotherapy and in combination with anti-VEGF therapy.
- The study emphasizes its potential clinical utility in underserved populations.
- An oral pill could be transformative for patients in regions with limited access to specialty doctors or who cannot afford or travel to monthly eye appointments.
Source: Med (Cell Press)
